Loading...
Market
Story
Pfizer's Talzenna-Xtandi Combo Significantly Prolongs Survival in Final Phase 3 Prostate Cancer Study
Oct 10, 2024, 10:55 AM
Pfizer announced that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly extended overall survival in men with metastatic castration-resistant prostate cancer (mCRPC), according to the final prespecified overall survival analysis of the phase 3 TALAPRO-2 trial. The study demonstrated that the drug combination significantly prolonged patients' lives compared to enzalutamide alone, offering a promising new treatment option for this aggressive form of prostate cancer.
View original story
Similar markets
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%